Clinical Trial · NCT01269593

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Overview

The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Early Phase 1

Contacts

Mark Dunphy, DO (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01269593

Drug / Compound

PUH71

Isotope(s):

Target(s):

HSP90

Ligand Class: Small Molecules

Eligibility

Inclusion

This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc).
Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol.
Age between 18-90
* Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology)
Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential

Exclusion

AST/ALT \>2.5 x ULN
Known hyperthyroidismHepatic:
* Previous allergic reaction to contrast medium.
Bilirubin \> 1.5 x institutional upper limit of normal (ULN)
Hypersensitivity to iodide products.